PROGRAM

Scientific Program

Session 1. GDM Pharmacotherapy

  1. Metformin in GDM: What do the data tell us?
    Janet Rowan (National Women’s Health, New Zealand)
  2. Is there a role for glyburide in the treatment of GDM?
    Christina M. Scifres (Indiana University School of Medicine, USA)
  3. Insulin therapy in GDM
    Eiji Kawasaki (Diabetes Center Shin-Koga Hospital, Japan)

Session 2. Clinical Study and Obstetrics

  1. How has COVID 19 changed GDM screening
    David McIntyre (The University of Queensland, Australia)
  2. Guidance on management of COVID 19 in pregnancy
    Liona Chiu Yee Poon (The Chinese University of Hong Kong, Hong Kong)
  3. Assessment of fetal well-being in diabetic pregnancy
    Tomoaki Ikeda (Mie University Graduate School of Medicine, Japan)

Session 3. Preexisting Diabetes

  1. EVOLVE study
    Elizabeth R. Mathiesen (University of Copenhagen / Rigshospitalet, Denmark)
  2. Lessons from the CONCEPTT trial
    Helen R. Murphy (University of East Anglia, UK)
  3. MITY trial
    Denice S. Feig (University of Toronto, Canada)

Session 4. Early GDM and Treatment

  1. Biomarkers in diagnosis of GDM
    Martin Overgaard (Odense University Hospital, Denmark)
  2. The TOBOGM trial
    David Simmons (Western Sydney University, Australia)
  3. EMERGE trial
    Fidelma Dunne (College of Medicine Nursing and Health Sciences, National University of Ireland, Ireland / Current Chairperson IADPSG)

Session 5. HAPO Study and F/U Study

  1. The HAPO study and development of IADPSG criteria
    Donald R. Coustan (Warren Alpert Medical School of Brown University, USA)
  2. HAPO follow-up study: Long-term metabolic health after GDM
    Boyd E. Metzger (Emeritus Tom D Spies Professor of Nutrition and Metabolism,
    Northwestern University Feinberg School of Medicine, USA)
  3. HAPO children follow up study
    Ronald C. Ma (The Chinese University of Hong Kong, Hong Kong)

Session 6. GDM and Obesity

  1. DALI study
    Rosa Corcoy (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona,PI, CIBER-BBN, Spain)
  2. Short and long term effects of obesity and excessive gestational weight gain in
    women and their children
    Patrick M. Catalano (Tufts University School of Medicine, USA)
  3. The importance of core outcome sets in diabetes and pregnancy
    Aoife M. Egan (Mayo Clinic Rochester, USA)

Session 7. T2 DM Prevention

  1. Prevention of type 2 diabetes – Experiences from the finnish diabetes prevention study
    Jaakko Tuomilehto (University of Helsinki, Finland)
  2. Breastfeeding: Preventive effect against the development of diabetes in women with a history of GDM
    Ichiro Yasuhi (NHO Nagasaki Medical Center, Japan)
  3. Lifestyle intervention using IoT devices and mobile apps for postpartum weight retention in obese pregnant women
    Naoko Arata (Center for Maternal-Fetal-Neonatal and Reproductive Medicine, National Center for Child Health and Development, Japan)

Session 8. Obstetrcis and Metabolism in Early Pregnancy

  1. Longitudinal changes in insulin secretory response across pregnancy
    Camille E. Powe (Harvard Medical School, USA)
  2. The human placenta in the first trimester of pregnancy: Effects of diabetes and obesity
    Gernot Desoye (Medical University of Graz Perinatal Research Laboratory, Austria)
  3. Epigenetics in early life, which affects obesity in later life
    Koshi Hashimoto (Dokkyo Medical University Saitama Medical Center, Japan)

Special lecture: IADPSG Lifetime Achievement Award

The path I walked fully ―Foundation of the field of diabetes and pregnancy―
Yasue Omori (Emeritus Professor of Tokyo Women’s Medical University / Honary Chairperson of the Japanese Society of Diabetes and Pregnancy, Japan)

Interactive Discussion Session using ZOOM (live stream)

Everyone can attend this session. However, this session will be held on November 15th (Sun) from 5:00 a.m. to 7:00 a.m. (Japanese Standard Time).